Uwe Gudat received his medical degree from the University of Marburg, Germany. He is licensed in internal medicine and diabetology as a sub-speciality, training under Michael Berger in Dusseldorf Germany.
Uwe Gudat joined the pharmaceutical industry in 1995 with Eli Lilly and since then has held positions at Hesperion/Actelion, Novartis and Merck Serono. In this time he has led global clinical development teams, served as global medical brand director, led clinical teams for in-licensing due-diligence and managed clinical-trial review, first in man transitions and product safety assessments. Currently he is Head of Safety of the Merck Serono Biosimilars Unit.
He has published a number of scientific papers in the field of diabetes and is currently on the editorial advisory board of Applied Clinical Trials.